{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:49:36Z","timestamp":1794487776845,"version":"4.9.1"},"reference-count":134,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T00:00:00Z","timestamp":1716681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Genetic biomarkers could potentially lower the risk of treatment failure in chronic inflammatory diseases (CID) like psoriasis, psoriatic arthritis (PsA), rheumatoid arthritis (RA), and inflammatory bowel disease (IBD). We performed a systematic review and meta-analysis assessing the association between single nucleotide polymorphisms (SNPs) and response to biologics. Odds ratio (OR) with 95% confidence interval (CI) meta-analyses were performed. In total, 185 studies examining 62,774 individuals were included. For the diseases combined, the minor allele of MYD88 (rs7744) was associated with good response to TNFi (OR: 1.24 [1.02\u20131.51], 6 studies, 3158 patients with psoriasis or RA) and the minor alleles of NLRP3 (rs4612666) (OR: 0.71 [0.58\u20130.87], 5 studies, 3819 patients with RA or IBD), TNF-308 (rs1800629) (OR: 0.71 [0.55\u20130.92], 25 studies, 4341 patients with psoriasis, RA, or IBD), FCGR3A (rs396991) (OR: 0.77 [0.65\u20130.93], 18 studies, 2562 patients with psoriasis, PsA, RA, or IBD), and TNF-238 (rs361525) (OR: 0.57 [0.34\u20130.96]), 7 studies, 818 patients with psoriasis, RA, or IBD) were associated with poor response to TNFi together or infliximab alone. Genetic variants in TNF\u03b1, NLRP3, MYD88, and FcR\u03b3 genes are associated with response to TNFi across several inflammatory diseases. Most other genetic variants associated with response were observed in a few studies, and further validation is needed.<\/jats:p>","DOI":"10.3390\/ijms25115793","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T10:14:07Z","timestamp":1716804847000},"page":"5793","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The Association between Genetics and Response to Treatment with Biologics in Patients with Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"25","author":[{"given":"Rownaq Fares","family":"Al-Sofi","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital\u2014Herlev and Gentofte, 1165 Copenhagen, Denmark"},{"name":"Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte Hospital, 2730 Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie Siewertsen","family":"Bergmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital\u2014Herlev and Gentofte, 1165 Copenhagen, Denmark"},{"name":"Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte Hospital, 2730 Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7543-9016","authenticated-orcid":false,"given":"Claus Henrik","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Center for Rheumatology and Spine Diseases, Institute for Inflammation Research, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Andersen","sequence":"additional","affiliation":[{"name":"Institute of Regional Health Research, University of Southern Denmark, 5230 Odense, Denmark"},{"name":"Molecular Diagnostics and Clinical Research Unit, Department of Internal Medicine, University Hospital of Southern Denmark, 6200 Aabenraa, Denmark"},{"name":"Institute of Molecular Medicine, University of Southern Denmark, 5230 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9680","authenticated-orcid":false,"given":"Lone","family":"Skov","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital\u2014Herlev and Gentofte, 1165 Copenhagen, Denmark"},{"name":"Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte Hospital, 2730 Herlev, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 1172 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2950-3280","authenticated-orcid":false,"given":"Nikolai","family":"Loft","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital\u2014Herlev and Gentofte, 1165 Copenhagen, Denmark"},{"name":"Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte Hospital, 2730 Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/gut.2009.199679","article-title":"New IBD genetics: Common pathways with other diseases","volume":"60","author":"Lees","year":"2011","journal-title":"Gut"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.smim.2009.04.002","article-title":"Unraveling the genetics of complex diseases: Susceptibility genes for rheumatoid arthritis and psoriasis","volume":"21","author":"Li","year":"2009","journal-title":"Semin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: Pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_8","first-page":"928461","article-title":"Role of Th17 Cells in the Pathogenesis of Human IBD","volume":"2014","year":"2014","journal-title":"ISRN Inflamm."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kany, S., Vollrath, J.T., and Relja, B. (2019). Cytokines in Inflammatory Disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20236008"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1172\/JCI124884","article-title":"IFN-\u03b3 drives inflammatory bowel disease pathogenesis through VE-cadherin\u2013directed vascular barrier disruption","volume":"129","author":"Langer","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/rheumatology\/kex186","article-title":"The role of IL-12\/23 in T cell-related chronic inflammation: Implications of immunodeficiency and therapeutic blockade","volume":"57","author":"Schurich","year":"2018","journal-title":"Rheumatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMct1209614","article-title":"Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease","volume":"369","author":"Nielsen","year":"2013","journal-title":"New Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","article-title":"New therapies for treatment of rheumatoid arthritis","volume":"370","author":"Smolen","year":"2007","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s10620-021-06932-4","article-title":"Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"67","author":"Honap","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","article-title":"Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review","volume":"22","author":"Thatiparthi","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"rkaa070","DOI":"10.1093\/rap\/rkaa070","article-title":"Persistence of biologic treatments in psoriatic arthritis: A population-based study in Sweden","volume":"4","author":"Geale","year":"2020","journal-title":"Rheumatol. Adv. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1038\/jid.2015.206","article-title":"Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis","volume":"135","author":"Nast","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/ibd\/izaa088","article-title":"The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative Colitis","volume":"27","author":"Grant","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/apt.12968","article-title":"Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis","volume":"40","author":"Baert","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jamadermatol.2022.1863","article-title":"Circulating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab","volume":"158","author":"Enevold","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e15106","DOI":"10.1111\/dth.15106","article-title":"Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis","volume":"34","author":"Loft","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Andersen, C.S.B., Kvist-Hansen, A., Siewertsen, M., Enevold, C., Hansen, P.R., Kaur-Knudsen, D., Zachariae, C., Nielsen, C.H., Loft, N., and Skov, L. (2023). Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076111"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/tpj.2017.31","article-title":"Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis","volume":"18","author":"Loft","year":"2017","journal-title":"Pharmacogenomics J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Conigliaro, P., Ciccacci, C., Politi, C., Triggianese, P., Rufini, S., Kroegler, B., Perricone, C., Latini, A., Novelli, G., and Borgiani, P. (2017). Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 Genes Are Associated with the Response to TNF Inhibitors in Patients with Rheumatoid Arthritis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0169956"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.phrs.2016.06.016","article-title":"Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis","volume":"111","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.3748\/wjg.v20.i13.3609","article-title":"Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn\u2019s disease","volume":"20","author":"Thomas","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_28","first-page":"147","article-title":"A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis","volume":"16","author":"Blanco","year":"2015","journal-title":"Pharmacogenomics J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jbspin.2014.08.006","article-title":"Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis","volume":"82","author":"Swierkot","year":"2015","journal-title":"Jt. Bone Spine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/tpj.2014.19","article-title":"Associations between functional polymorphisms in the NF\u03baB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease","volume":"14","author":"Bank","year":"2014","journal-title":"Pharmacogenomics J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/exd.14215","article-title":"Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs","volume":"29","author":"Sabador","year":"2020","journal-title":"Exp. Dermatol."},{"key":"ref_32","first-page":"70","article-title":"New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis","volume":"18","author":"Cabaleiro","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"E611","DOI":"10.1111\/jdv.18870","article-title":"Association between HLA-Cw6 and response to treatment with biologics in patients with psoriasis: A systematic review and meta-analysis","volume":"37","author":"Siewertsen","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/pgs-2017-0014","article-title":"Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis","volume":"18","author":"Belmonte","year":"2017","journal-title":"Pharmacogenomics"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/jdv.13024","article-title":"TNF-alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients","volume":"29","author":"Farina","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.12425","article-title":"The relationship between tumour necrosis factor (TNF)-\u03b1 promoter andIL12B\/IL-23Rgenes polymorphisms and the efficacy of anti-TNF-\u03b1 therapy in psoriasis: A case-control study","volume":"169","author":"Gallo","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_38","first-page":"240","article-title":"The effect of TnFaip3 gene polymorphism on disease susceptibility and response of etanercept in psoriatic patients","volume":"7","author":"Abbas","year":"2020","journal-title":"Eur. J. Mol. Clin. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03256427","article-title":"Pharmacogenetic Analysis of TNF, TNFRSF1A, and TNFRSF1B Gene Polymorphisms and Prediction of Response to Anti-TNF Therapy in Psoriasis Patients in the Greek Population","volume":"16","author":"Vasilopoulos","year":"2012","journal-title":"Mol. Diagn. Ther."},{"key":"ref_40","first-page":"E110","article-title":"Lack of association of TNFA, TNFRSF1B and TNFAIP3 gene polymorphisms with response to anti-tumor necrosis factor therapy in Japanese patients with psoriasis","volume":"47","author":"Ito","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2217\/pgs-2017-0143","article-title":"Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis","volume":"19","author":"Reolid","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref_42","first-page":"405","article-title":"The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients","volume":"307","author":"Batalla","year":"2014","journal-title":"Arch. Dermatol. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14712598.2021.1862082","article-title":"HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis","volume":"21","author":"Morelli","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_44","first-page":"112","article-title":"Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: Results from a multicentre study of four European psoriasis cohorts","volume":"34","author":"Reek","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3109\/03009741003781969","article-title":"Association between theFCGR3AV158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients","volume":"39","author":"Pedrero","year":"2010","journal-title":"Scand. J. Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3899\/jrheum.110980","article-title":"FCGR2A\/CD32AandFCGR3A\/CD16AVariants and EULAR Response to Tumor Necrosis Factor-\u03b1 Blockers in Psoriatic Arthritis: A Longitudinal Study with 6 Months of Followup","volume":"39","author":"Montilla","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar2990","article-title":"Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: A prospective case-only study","volume":"12","author":"Calaza","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/FPC.0b013e3283544043","article-title":"Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNF\u03b1 inhibitors in patients with rheumatoid arthritis","volume":"22","author":"Krintel","year":"2012","journal-title":"Pharmacogenetics Genom."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2119\/2008-00056.Liu","article-title":"Genome-Wide Association Scan Identifies Candidate Polymorphisms Associated with Differential Response to Anti-TNF Treatment in Rheumatoid Arthritis","volume":"14","author":"Liu","year":"2008","journal-title":"Mol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Sode, J., Vogel, U., Bank, S., Andersen, P.S., Thomsen, M.K., Hetland, M.L., Locht, H., Heegaard, N.H.H., and Andersen, V. (2014). Anti-TNF Treatment Response in Rheumatoid Arthritis Patients Is Associated with Genetic Variation in the NLRP3-Inflammasome. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100361"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/tpj.2016.66","article-title":"Confirmation of an IRAK3 polymorphism as a genetic marker predicting response to anti-TNF treatment in rheumatoid arthritis","volume":"18","author":"Sode","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lopez-Rodriguez, R., Perez-Pampin, E., Marquez, A., Blanco, F.J., Joven, B., Carreira, P., Ferrer, M.A., Caliz, R., Valor, L., and Narvaez, J. (2018). Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0196793"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/rheumatology\/keh550","article-title":"The influence of a polymorphism at position -857 of the tumour necrosis factor gene on clinical response to etanercept therapy in rheumatoid arthritis","volume":"44","author":"Kang","year":"2005","journal-title":"Rheumatology"},{"key":"ref_54","first-page":"340","article-title":"Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy","volume":"26","author":"Rooryck","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2217\/pgs.14.175","article-title":"FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors","volume":"16","author":"Montes","year":"2015","journal-title":"Pharmacogenomics."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/art.22390","article-title":"Fc\u03b3 receptor type IIIA genotype and response to tumor necrosis factor \u03b1\u2013blocking agents in patients with rheumatoid arthritis","volume":"56","author":"Kastbom","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2217\/pgs.14.178","article-title":"FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis","volume":"16","author":"Huizinga","year":"2015","journal-title":"Pharmacogenomics."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1136\/ard.2008.096982","article-title":"Influence of variants of Fc\u03b3 receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor \u03b1 therapy in rheumatoid arthritis","volume":"68","author":"Canete","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1136\/ard.2007.086892","article-title":"A polymorphism in the gene encoding the Fc [GAMMA] IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis","volume":"67","author":"Tsukahara","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1002\/art.21266","article-title":"Fc\u03b3 receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor \u03b1\u2013blocking agents","volume":"52","author":"Tutuncu","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/FPC.0000000000000042","article-title":"Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis","volume":"24","author":"Montes","year":"2014","journal-title":"Pharmacogenetics Genom."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2217\/pgs-2017-0047","article-title":"Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis","volume":"18","author":"Eektimmerman","year":"2017","journal-title":"Pharmacogenomics"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Avila-Pedretti, G., Tornero, J., Fern\u00e1ndez-Nebro, A., Blanco, F., Gonz\u00e1lez-Alvaro, I., Ca\u00f1ete, J.D., Maym\u00f3, J., Alperiz, M., Fern\u00e1ndez-Guti\u00e9rrez, B., and Oliv\u00e9, A. (2015). Variation at FCGR2A and Functionally Related Genes Is Associated with the Response to Anti-TNF Therapy in Rheumatoid Arthritis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122088"},{"key":"ref_64","first-page":"636","article-title":"Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients","volume":"52","author":"Rouanet","year":"2012","journal-title":"Rheumatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/art.37707","article-title":"The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers","volume":"65","author":"Fabris","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e001524","DOI":"10.1136\/bmjopen-2012-001524","article-title":"Influence ofFCGR3Agenotype on the therapeutic response to rituximab in rheumatoid arthritis: An observational cohort study","volume":"2","author":"Kastbom","year":"2012","journal-title":"BMJ Open"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e000485","DOI":"10.1136\/rmdopen-2017-000485","article-title":"Effect of Fc\u03b3-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis","volume":"3","author":"Szamosi","year":"2017","journal-title":"RMD Open"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/jcph.1341","article-title":"FCGR2A\/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis","volume":"59","author":"Morales","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/annrheumdis-2012-202435","article-title":"The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: Results of an Italian multicentre study","volume":"73","author":"Quartuccio","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/annrheumdis-2011-200337","article-title":"Fc\u03b3 receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab","volume":"71","author":"Rouanet","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_71","first-page":"167","article-title":"Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis","volume":"18","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41397-019-0072-6","article-title":"A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients","volume":"19","author":"Luxembourger","year":"2019","journal-title":"Pharmacogenomics J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/FPC.0000000000000071","article-title":"Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis","volume":"24","author":"Enevold","year":"2014","journal-title":"Pharmacogenetics Genom."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/sj.gene.6364228","article-title":"Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis","volume":"6","author":"Camp","year":"2005","journal-title":"Genes Immun."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Pete, N.M., Montoro, M.d.M.M., Ram\u00edrez, C.P., Mart\u00ednez, F.M., de la Plata, J.E.M., Daddaoua, A., and Morales, A.J. (2021). Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis. J. Pers. Med., 11.","DOI":"10.3390\/jpm11060573"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12016-017-8603-x","article-title":"Memory B Cells and Response to Abatacept in Rheumatoid Arthritis","volume":"53","author":"Gazeau","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1097\/MIB.0000000000001150","article-title":"Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD","volume":"23","author":"Yoon","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/ibd\/izy083","article-title":"Genetic Markers Predict Primary Nonresponse and Durable Response to Anti\u2013Tumor Necrosis Factor Therapy in Ulcerative Colitis","volume":"24","author":"Khalili","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/apt.15187","article-title":"Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease","volume":"49","author":"Bank","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Urabe, S., Isomoto, H., Ishida, T., Maeda, K., Inamine, T., Kondo, S., Higuchi, N., Sato, K., Uehara, R., and Yajima, H. (2015). Genetic Polymorphisms ofIL-17FandTRAF3IP2Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn\u2019s Disease. BioMed Res. Int., 2015.","DOI":"10.1155\/2015\/416838"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MPG.0000000000002840","article-title":"Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease","volume":"71","author":"Bossacoma","year":"2020","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.3748\/wjg.v23.i27.4958","article-title":"Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn\u2019s disease","volume":"23","author":"Netz","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Matsuoka, K., Hamada, S., Shimizu, M., Nanki, K., Mizuno, S., Kiyohara, H., Arai, M., Sugimoto, S., Iwao, Y., and Ogata, H. (2018). Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn\u2019s disease. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0204632"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2036.2004.01871.x","article-title":"Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn\u2019s disease","volume":"19","author":"Louis","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_85","first-page":"35","article-title":"Association of TNF and Fc\u03b3RIIA gene polymorphisms with differential response to infliximab in a Greek cohort of crohn\u2019s disease patients","volume":"24","author":"Papamichaela","year":"2011","journal-title":"Ann Gastroenterol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/cts.13075","article-title":"Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease","volume":"14","author":"Curci","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/01.fpc.0000230421.12844.fd","article-title":"Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn\u2019s disease: A subanalysis of the ACCENT I study","volume":"16","author":"Louis","year":"2006","journal-title":"Pharmacogenetics Genom."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Hoffmann, P., Lamerz, D., Hill, P., Kirchner, M., and Gauss, A. (2021). Gene Polymorphisms of NOD2, IL23R, PTPN2 and ATG16L1 in Patients with Crohn\u2019s Disease: On theWay to Personalized Medicine?. Genes, 12.","DOI":"10.3390\/genes12060866"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1136\/ard.2009.117309","article-title":"Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF B signalling pathways","volume":"69","author":"Potter","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Zervou, M.I., Myrthianou, E., Flouri, I., Plant, D., Chlouverakis, G., Castro-Giner, F., Rapsomaniki, P., Barton, A., Boumpas, D.T., and Sidiropoulos, P. (2013). Lack of Association of Variants Previously Associated with Anti-TNF Medication Response in Rheumatoid Arthritis Patients: Results from a Homogeneous Greek Population. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0074375"},{"key":"ref_91","first-page":"137","article-title":"Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis","volume":"16","author":"Montes","year":"2015","journal-title":"Pharmacogenomics J."},{"key":"ref_92","first-page":"701","article-title":"Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-\u03b1 response in rheumatoid arthritis","volume":"29","author":"Vasilopoulos","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2478\/jomb-2014-0060","article-title":"Influence Of Promoter Polymorphisms Of The Tnf-\u03b1 (-308g\/A) And IL-6 (-174g\/C) Genes On Therapeutic Response To Etanercept In Rheumatoid Arthritis","volume":"34","author":"Damjanov","year":"2015","journal-title":"J. Med Biochem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/03009740600904284","article-title":"Tumour necrosis factor (TNF)\u03b1 \u2212308 G\/G promoter polymorphism and TNF\u03b1 levels correlate with a better response to adalimumab in patients with rheumatoid arthritis","volume":"35","author":"Cuchacovich","year":"2006","journal-title":"Scand. J. Rheumatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/ard.62.6.526","article-title":"Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis","volume":"62","author":"Padyukov","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/art.23092","article-title":"Influence of \u2212308 A\/G polymorphism in the tumor necrosis factor \u03b1 gene on etanercept treatment in rheumatoid arthritis","volume":"57","author":"Guis","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_97","first-page":"546","article-title":"Polymorphisms in genes encoding tumor necrosis factor-\u03b1 and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis","volume":"35","author":"Pinto","year":"2008","journal-title":"J Rheumatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/hmg\/ddn245","article-title":"Braggss Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis","volume":"17","author":"Maxwell","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_99","first-page":"478","article-title":"A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis","volume":"67","author":"Comets","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/art.23430","article-title":"Association between the level of circulating bioactive tumor necrosis factor \u03b1 and the tumor necrosis factor \u03b1 gene polymorphism at \u2212308 in patients with rheumatoid arthritis treated with a tumor necrosis factor \u03b1 inhibitor","volume":"58","author":"Marotte","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/gas.37.7.818.824","article-title":"Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With -308 TNF Gene Polymorphism","volume":"37","author":"Louis","year":"2002","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/01.fpc.0000230117.26581.a4","article-title":"The TNF\/ADAM 17 system: Implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn\u2019s disease","volume":"16","author":"Dideberg","year":"2006","journal-title":"Pharmacogenetics Genom."},{"key":"ref_103","first-page":"63","article-title":"Genetic polymorphisms of tumour necrosis factor alpha (TNF-\u03b1) promoter gene and response to TNF-\u03b1 inhibitors in Spanish patients with inflammatory bowel disease","volume":"41","author":"Campillo","year":"2013","journal-title":"Int. J. Immunogenetics"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1365-2036.2009.03926.x","article-title":"Infliximab dependency in children with Crohn\u2019s disease","volume":"29","author":"Duricova","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/tpj.2016.16","article-title":"FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNF\u03b1 inhibitors","volume":"17","author":"Mendrinou","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jamadermatol.2013.4632","article-title":"The Role of Fc\u03b3 Receptor Polymorphisms in the Response to Anti\u2013Tumor Necrosis Factor Therapy in Psoriasis","volume":"149","author":"Guilabert","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/jamadermatol.2015.2818","article-title":"Influence of Fc\u03b3 Receptor Polymorphisms on Response to Anti\u2013Tumor Necrosis Factor Treatment in Psoriasis","volume":"151","author":"Batalla","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2217\/pgs.15.107","article-title":"The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis","volume":"16","author":"Cabaleiro","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/FPC.0000000000000233","article-title":"HLA-Cw6 allele, NFkB1 and NFkBIA polymorphisms play no role in predicting response to etanercept in psoriatic patients","volume":"26","author":"Caldarola","year":"2016","journal-title":"Pharmacogenetics Genom."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/art.11168","article-title":"Polymorphism at position \u2212308 of the tumor necrosis factor \u03b1 gene influences outcome of infliximab therapy in rheumatoid arthritis","volume":"48","author":"Mugnier","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/03009740410005863","article-title":"Tumour necrosis factor?? (TNF??) levels and influence of ?308 TNF?? promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis","volume":"33","author":"Cuchacovich","year":"2004","journal-title":"Scand. J. Rheumatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/rheumatology\/kem041","article-title":"Combined tumour necrosis factor- and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients\u2019 response to anti-TNF- therapy and explain controversies of studies based on a single polymorphism","volume":"46","author":"Chatzikyriakidou","year":"2007","journal-title":"Rheumatology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jbspin.2012.02.003","article-title":"Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis","volume":"79","author":"Pedrero","year":"2012","journal-title":"Jt. Bone Spine"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1365-2036.2008.03630.x","article-title":"Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn\u2019s disease","volume":"27","author":"Matsukura","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.humimm.2013.09.017","article-title":"Role of TNFRSF1B polymorphisms in the response of Crohn\u2019s disease patients to infliximab","volume":"75","author":"Medrano","year":"2013","journal-title":"Hum. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/ard.2008.088138","article-title":"The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis","volume":"67","author":"Toonen","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jbspin.2013.12.005","article-title":"TNFRII polymorphism is associated with response to TNF blockers in rheumatoid arthritis patients seronegative for ACPA","volume":"81","author":"Pers","year":"2014","journal-title":"Jt. Bone Spine"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/FPC.0000000000000140","article-title":"Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs","volume":"25","author":"Canet","year":"2015","journal-title":"Pharmacogenetics Genom."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/sj.tpj.6500091","article-title":"Pharmacogenetic investigation of the TNF\/TNF-receptor system in patients with chronic active Crohn\u2019s disease treated with infliximab","volume":"2","author":"Mascheretti","year":"2002","journal-title":"Pharmacogenomics J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/apt.12010","article-title":"Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and\/or acute severe infusion reactions to infliximab in Crohn\u2019s disease","volume":"36","author":"Steenholdt","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2217\/pgs-2021-0019","article-title":"Exploring pharmacogenetic variants for predicting response to anti-TNF therapy in autoimmune diseases: A meta-analysis","volume":"22","author":"Antonatos","year":"2021","journal-title":"Pharmacogenomics"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/tpj.2009.7","article-title":"TNF-\u03b1 \u2212308 G\/A polymorphism and responsiveness to TNF-\u03b1 blockade therapy in moderate to severe rheumatoid arthritis: A systematic review and meta-analysis","volume":"9","author":"Roslin","year":"2009","journal-title":"Pharmacogenomics J."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Bank, S., Andersen, P.S., Burisch, J., Pedersen, N., Roug, S., Galsgaard, J., Turino, S.Y., Brodersen, J.B., Rashid, S., and Rasmussen, B.K. (2014). Polymorphisms in the Inflammatory Pathway Genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG Are Associated with Susceptibility of Inflammatory Bowel Disease in a Danish Cohort. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098815"},{"key":"ref_124","first-page":"1054","article-title":"Dissection of the FCGR3A association with RA: Increased association in men and with autoantibody positive disease","volume":"69","author":"Barrett","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/ng.482","article-title":"A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population","volume":"41","author":"Asano","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_126","first-page":"2561","article-title":"Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc\u03b3RIIIa-158 V\/V and V\/F polymorphism","volume":"110","author":"Hatjiharissi","year":"2007","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_127","first-page":"1109","article-title":"Fc\u03b3RIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc\u03b3RIIIa, independently of the Fc\u03b3RIIIa-48L\/R\/H phenotype","volume":"90","author":"Koene","year":"1997","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"104343","DOI":"10.1016\/j.ebiom.2022.104343","article-title":"Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity","volume":"86","author":"Robinson","year":"2022","journal-title":"EBioMedicine"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","article-title":"Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: A meta-analysis","volume":"72","author":"Isaacs","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/annrheumdis-2013-205094","article-title":"Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis","volume":"73","author":"Sandberg","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_131","first-page":"CD011972","article-title":"Lifestyle changes for treating psoriasis","volume":"2019","author":"Ko","year":"2019","journal-title":"Emergencias"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ijo.2015.64","article-title":"Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: A systematic review and meta-analysis","volume":"39","author":"Upala","year":"2015","journal-title":"Int. J. Obes."},{"key":"ref_133","first-page":"2130","article-title":"Association between tobacco smoking and response to tumour necrosis factor \u03b1 inhibitor treatment in psoriatic arthritis: Results from the DANBIO registry","volume":"74","author":"Glintborg","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"adv00579","DOI":"10.2340\/actadv.v101.351","article-title":"Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study","volume":"101","author":"Schwarz","year":"2021","journal-title":"Acta Derm. Venereol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/11\/5793\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:49:04Z","timestamp":1760107744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/11\/5793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,26]]},"references-count":134,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["ijms25115793"],"URL":"https:\/\/doi.org\/10.3390\/ijms25115793","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,26]]}}}